메뉴 건너뛰기




Volumn 31, Issue 11, 2016, Pages 1887-1894

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: Results of the TEMPO 3:4 Trial

Author keywords

ADPKD; albuminuria; chronic renal failure; eGFR; vasopressin

Indexed keywords

ALBUMIN; CREATININE; PLACEBO; TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

EID: 84996598645     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv422     Document Type: Article
Times cited : (40)

References (27)
  • 1
    • 78650610154 scopus 로고    scopus 로고
    • Intensive blood-pressure control in hypertensive chronic kidney disease
    • Appel LJ,Wright JT, Jr, Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918-929
    • (2010) N Engl J Med , vol.363 , pp. 918-929
    • Appel, L.J.1    Wright, J.T.2    Greene, T.3
  • 2
    • 79958817916 scopus 로고    scopus 로고
    • Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes A collaborative meta-analysis of general and high-risk population cohorts
    • Gansevoort RT,Matsushita K, van der VeldeMet al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80: 93-104
    • (2011) Kidney Int , vol.80 , pp. 93-104
    • Gansevoort, R.T.1    Matsushita, K.2    Van Der Velde, M.3
  • 3
    • 79957827666 scopus 로고    scopus 로고
    • Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease A collaborative meta-analysis of kidney disease population cohorts
    • Astor BC, Matsushita K, Gansevoort RT et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79: 1331-1340
    • (2011) Kidney Int , vol.79 , pp. 1331-1340
    • Astor, B.C.1    Matsushita, K.2    Gansevoort, R.T.3
  • 4
    • 85047697782 scopus 로고
    • Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease
    • Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 1995; 10: 497-504
    • (1995) Nephrol Dial Transplant , vol.10 , pp. 497-504
    • Gansevoort, R.T.1    De Zeeuw, D.2    De Jong, P.E.3
  • 5
    • 0028887054 scopus 로고
    • Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials
    • Gansevoort RT, Sluiter WJ, HemmelderMHet al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-1974
    • (1995) Nephrol Dial Transplant , vol.10 , pp. 1963-1974
    • Gansevoort, R.T.1    Sluiter, W.J.2    Hemmelder, M.H.3
  • 6
    • 46049091172 scopus 로고    scopus 로고
    • Effects of strict blood pressure control by a long-acting calcium channel blocker on brain natriuretic peptide and urinary albumin excretion rate in Japanese hypertensive patients
    • Uno H, Ishikawa J, Hoshide S et al. Effects of strict blood pressure control by a long-acting calcium channel blocker on brain natriuretic peptide and urinary albumin excretion rate in Japanese hypertensive patients. Hypertens Res 2008; 31: 887-896
    • (2008) Hypertens Res , vol.31 , pp. 887-896
    • Uno, H.1    Ishikawa, J.2    Hoshide, S.3
  • 7
    • 0028838569 scopus 로고
    • Blood pressure control, proteinuria, and the progression of renal disease the modification of diet in renal disease study
    • Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. the modification of diet in renal disease study. Ann Intern Med 1995; 123: 754-762
    • (1995) Ann Intern Med , vol.123 , pp. 754-762
    • Peterson, J.C.1    Adler, S.2    Burkart, J.M.3
  • 8
    • 0030979322 scopus 로고    scopus 로고
    • Predictors of the progression of renal disease in the modification of diet in renal disease study
    • Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int 1997; 51: 1908-1919
    • (1997) Kidney Int , vol.51 , pp. 1908-1919
    • Hunsicker, L.G.1    Adler, S.2    Caggiula, A.3
  • 9
    • 0035902622 scopus 로고    scopus 로고
    • Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease A meta-analysis of patient-level data
    • Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
    • (2001) Ann Intern Med , vol.135 , pp. 73-87
    • Jafar, T.H.1    Schmid, C.H.2    Landa, M.3
  • 10
    • 65249111029 scopus 로고    scopus 로고
    • Lowering blood pressure reduces renal events in type 2 diabetes
    • de Galan BE, Perkovic V, Ninomiya T et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20: 883-892
    • (2009) J Am Soc Nephrol , vol.20 , pp. 883-892
    • De Galan, B.E.1    Perkovic, V.2    Ninomiya, T.3
  • 11
    • 84880922135 scopus 로고    scopus 로고
    • Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention
    • Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339-352
    • (2013) Lancet , vol.382 , pp. 339-352
    • Gansevoort, R.T.1    Correa-Rotter, R.2    Hemmelgarn, B.R.3
  • 12
    • 0028725184 scopus 로고
    • Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease
    • Chapman AB, Johnson AM, Gabow PA et al. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5: 1349-1354
    • (1994) J Am Soc Nephrol , vol.5 , pp. 1349-1354
    • Chapman, A.B.1    Johnson, A.M.2    Gabow, P.A.3
  • 13
    • 0031667544 scopus 로고    scopus 로고
    • Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease
    • Sharp C, Johnson A, Gabow P. Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1998; 9: 1908-1914
    • (1998) J Am Soc Nephrol , vol.9 , pp. 1908-1914
    • Sharp, C.1    Johnson, A.2    Gabow, P.3
  • 14
    • 0031728322 scopus 로고    scopus 로고
    • Microalbuminuria in normotensive patients with autosomal-dominant polycystic kidney disease
    • Martinez-Vea A, Gutierrez C, Bardaji A et al. Microalbuminuria in normotensive patients with autosomal-dominant polycystic kidney disease. Scand J Urol Nephrol 1998; 32: 356-359
    • (1998) Scand J Urol Nephrol , vol.32 , pp. 356-359
    • Martinez-Vea, A.1    Gutierrez, C.2    Bardaji, A.3
  • 15
    • 77958456505 scopus 로고    scopus 로고
    • Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: A cross-sectional analysis
    • Meijer E, Boertien WE, Nauta FL et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis 2010; 56: 883-895
    • (2010) Am J Kidney Dis , vol.56 , pp. 883-895
    • Meijer, E.1    Boertien, W.E.2    Nauta, F.L.3
  • 16
    • 77953305179 scopus 로고    scopus 로고
    • Early renal abnormalities in autosomal dominant polycystic kidney disease
    • Meijer E, Rook M, Tent H et al. Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5: 1091-1098
    • (2010) Clin J Am Soc Nephrol , vol.5 , pp. 1091-1098
    • Meijer, E.1    Rook, M.2    Tent, H.3
  • 17
    • 32644459917 scopus 로고    scopus 로고
    • A comparative study of three kidney biomarker tests in autosomal-dominant polycystic kidney disease
    • Casal JA, Hermida J, Lens XM et al. A comparative study of three kidney biomarker tests in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68: 948-954
    • (2005) Kidney Int , vol.68 , pp. 948-954
    • Casal, J.A.1    Hermida, J.2    Lens, X.M.3
  • 18
    • 79953011165 scopus 로고    scopus 로고
    • Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease
    • Torres VE, Grantham JJ, Chapman AB et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 640-647
    • (2011) Clin J Am Soc Nephrol , vol.6 , pp. 640-647
    • Torres, V.E.1    Grantham, J.J.2    Chapman, A.B.3
  • 19
    • 84871303897 scopus 로고    scopus 로고
    • Tolvaptan in patients with autosomal dominant polycystic kidney disease
    • Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-2418
    • (2012) N Engl J Med , vol.367 , pp. 2407-2418
    • Torres, V.E.1    Chapman, A.B.2    Devuyst, O.3
  • 20
    • 79954622171 scopus 로고    scopus 로고
    • Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study
    • Torres VE, Meijer E, Bae KT et al. Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study.AmJ Kidney Dis 2011; 57: 692-699
    • (2011) AmJ Kidney Dis , vol.57 , pp. 692-699
    • Torres, V.E.1    Meijer, E.2    Bae, K.T.3
  • 21
    • 65649142017 scopus 로고    scopus 로고
    • A new equation to estimate glomerular filtration rate
    • Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
    • (2009) Ann Intern Med , vol.150 , pp. 604-612
    • Levey, A.S.1    Stevens, L.A.2    Schmid, C.H.3
  • 22
    • 79959500985 scopus 로고    scopus 로고
    • Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease
    • Meijer E, Boertien WE, Zietse R et al. Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease. Kidney Blood Press Res 2011; 34: 235-244
    • (2011) Kidney Blood Press Res , vol.34 , pp. 235-244
    • Meijer, E.1    Boertien, W.E.2    Zietse, R.3
  • 23
    • 0346666698 scopus 로고    scopus 로고
    • Vasopressin increases urinary albumin excretion in rats and humans: Involvement of V2 receptors and the renin-angiotensin system
    • Bardoux P, Bichet DG, Martin H et al. Vasopressin increases urinary albumin excretion in rats and humans: Involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003; 18: 497-506
    • (2003) Nephrol Dial Transplant , vol.18 , pp. 497-506
    • Bardoux, P.1    Bichet, D.G.2    Martin, H.3
  • 24
    • 79960426743 scopus 로고    scopus 로고
    • Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease
    • IrazabalMV, Torres VE, HoganMCet al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011; 80: 295-301
    • (2011) Kidney Int , vol.80 , pp. 295-301
    • Irazabal, M.V.1    Torres, V.E.2    Hogan, M.C.3
  • 25
    • 84888646403 scopus 로고    scopus 로고
    • Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease
    • Boertien WE,Meijer E, de Jong PE et al. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int 2013; 84: 1278-1286
    • (2013) Kidney Int , vol.84 , pp. 1278-1286
    • Boertien, W.E.1    Meijer, E.2    De Jong, P.E.3
  • 26
    • 84930439449 scopus 로고    scopus 로고
    • Short-term effects of tolvaptan in subjects with ADPKD at various levels of kidney function
    • Boertien WE, Meijer E, de Jong PE et al. Short-term effects of tolvaptan in subjects with ADPKD at various levels of kidney function. Am J Kidney Dis 2015; 65: 833-841
    • (2015) Am J Kidney Dis , vol.65 , pp. 833-841
    • Boertien, W.E.1    Meijer, E.2    De Jong, P.E.3
  • 27
    • 77950256964 scopus 로고    scopus 로고
    • Glomerular and proximal tubule cysts as early manifestations of Pkd1 deletion
    • Ahrabi AK, Jouret F, Marbaix E et al. Glomerular and proximal tubule cysts as early manifestations of Pkd1 deletion. Nephrol Dial Transplant 2010; 25: 1067-1078
    • (2010) Nephrol Dial Transplant , vol.25 , pp. 1067-1078
    • Ahrabi, A.K.1    Jouret, F.2    Marbaix, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.